Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

193 results about "Co medication" patented technology

Application of SRC inhibitor combined with KRAS-G12C inhibitor in preparation of medicine for treating KRAS-G12C mutant lung cancer and medicine composition

The invention provides application of an SRC inhibitor combined with a KRAS-G12C inhibitor to preparation of a medicine for treating KRAS-G12C mutant lung cancer and a medicine composition, and relates to the technical field of biological medicine, compared with independent use of the KRAS-G12C inhibitor, the scheme of the SRC inhibitor combined with the KRAS-G12C inhibitor can effectively inhibit proliferation and survival of KRAS-G12C mutant lung cancer cells, and the application of the SRC inhibitor combined with the KRAS-G12C inhibitor to preparation of the medicine for treating the KRAS-G12C mutant lung cancer can be used for preparing the medicine for treating the KRAS-G12C mutant lung cancer. The compound can effectively inhibit the activation of a KRAS-MARK pathway and an SRC-FAK pathway, the combination of the compound and the compound has a synergistic anti-tumor effect, and the compound and the compound can be directly combined for medication, can also be prepared into a combined preparation for treating KRAS mutant lung cancer, and have a good clinical transformation prospect.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV

Application of combined medicine composition in preparation of medicine for resisting transforming follicular lymphoma

The invention relates to application of a combined pharmaceutical composition in preparation of a medicine for resisting transforming follicular lymphoma. Active components in the combined pharmaceutical composition comprise a first component and a second component, the first component is selected from any one or a combination of at least two of sitagliflozin, pharmaceutically acceptable salt, isomer, solvate and metabolite of sitagliflozin; and the second component is selected from any one or a combination of at least two of chidamide, pharmaceutically acceptable salts, isomers, solvates and metabolites of the chidamide. Research finds that the combined use of the two active components not only can reduce the dosage of each drug and improve the medication safety, but also has the effect of improving or treating convertible follicular lymphoma more remarkably than that of a single drug active component, and plays a role in synergistic promotion. The invention provides an effective drug combination strategy for improvement or treatment of convertible follicular lymphoma, and has very significant significance.
Owner:THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIV +2

Whole-process targeting polypeptide, drug compound thereof, drug delivery system and application of whole-process targeting polypeptide

The invention provides a whole-process targeting polypeptide, a drug compound thereof, a drug delivery system and application of the whole-process targeting polypeptide. The whole-process targeting polypeptide comprises pHA and VAP which are covalently connected through a bridging structure; the VAP is LVAP, a reverse sequence polypeptide of the LVAP, DVAP or SVAP; wherein the amino acid sequence of the LVAP is as shown in SEQ ID NO: 1; the SVAP is a D-configuration polypeptide of the LVAP; the DVAP is a D-configuration polypeptide of the LVAP inverted sequence polypeptide; the bridging structure is amino-monoethylene glycol-carboxylic acid or a derivative thereof. The whole-process targeting polypeptide not only can cross a blood-brain barrier, target tumor neovascularization, cross a blood-tumor barrier, target tumor mimicry vessels, tumor cells and stem cells thereof, but also has better tumor cell affinity, anti-tumor treatment and in-vivo safety effects. Meanwhile, the drug compound or the drug delivery system has a synergistic effect after being combined with a chemotherapeutic drug, and the anti-tumor drug effect can be remarkably improved.
Owner:FUDAN UNIVERSITY

Application of Nintedanib and plant-derived cyclic peptide combined medicine in preparation of medicine for treating pulmonary fibrosis

The invention belongs to the technical field of medicines, and provides application of Nintedanib and a plant-derived cyclic peptide and radix pseudostellariae cyclic peptide B combined medicine in preparation of a medicine for treating pulmonary fibrosis, the Nintedanib and the plant-derived cyclic peptide and radix pseudostellariae cyclic peptide B combined medicine can play a synergistic effect, and the inhibition effect on the pulmonary fibrosis process is remarkably improved. The toxic and side effects of diarrhea and intestinal mucosa injury caused by nintedanib are reduced, and a good choice is provided for clinical treatment of pulmonary fibrosis.
Owner:CHINA PHARM UNIV

Application of combination of osimertinib and saquinavir in preparation of medicine for treating EGFR-TKI drug-resistant non-small cell lung cancer

The invention provides application of osimertinib and saquinavir in preparation of a medicine for treating EGFR-TKI drug-resistant non-small cell lung cancer, and belongs to the technical field of biological medicine. According to the invention, osimertinib and saquinavir are combined for medication, the inhibition rate of EGFR-TKI resistant non-small cell lung cancer is obviously higher than that of single medication, the combined medication of osimertinib and saquinavir has a synergistic inhibition effect, and the inhibition efficiency is higher than that of osimertinib and rimonabant. The experimental result of the invention provides a theoretical basis for clinical drug combination of osimertinib and saquinavir and an effective scheme of NSCLC for treating EGFR-TKI drug resistance, and has a wide application prospect in the field of medicine and pharmacology.
Owner:WUXI PEOPLES HOSPITAL

Method and device for determining drug combination and storage medium

The invention discloses a method for determining drug combination, which comprises the following steps: constructing a calculation model, and constructing the calculation model according to a response surface method; obtaining a reaction value, and inputting the reaction value to the calculation model, the reaction value including a factor main effect and a multi-factor interaction effect; a regression algorithm adapted to the relationship between the reaction variable and the reaction value; the optimal solution of the drug combination is obtained, the obtaining mode of the optimal solution is obtained from the regression algorithm, and the method further comprises a corresponding device and a storage medium. The method has the advantages that the calculation model for drug combination is constructed through the response surface method, the optimal solution of drug combination is obtained through calculation by inputting the factors, and compared with an exhaustion mode in the prior art, the efficiency is higher, and more time, manpower and resource consumption are saved.
Owner:SHANGHAI SHANGYONG TECH CO LTD

Drug combination of purinostat mesylate and analog thereof for preventing and treating multiple myeloma, and use thereof

A drug combination of purinostat mesylate and an analog thereof for preventing and treating multiple myeloma, and the use thereof. Specifically, provided is a three-drug or four-drug combination of purinostat mesylate and an analog thereof, dexamethasone and other drug, which drug combination has significantly enhanced synergistic anti-tumor activity in vitro and in vivo, synergistically inhibits the expression of the key survival protein in multiple myeloma, is superior to existing clinical combination regimens, and has no significant toxic side effects. In addition, the drug combination significantly down-regulates the expression of CDK6, and overcomes the drug resistance to an immunomodulator. In particular, the three-drug combination of puisostat mesylate, a glucocorticoid and an immunomodulator has an excellent prevention and treatment effect on multiple myeloma, especially relapsed / refractory multiple myeloma.
Owner:CHENGDU ZENITAR BIOMEDICAL TECH CO LTD

Purinostat mesylate for preventing and treating diffuse large b-cell lymphoma, analogue thereof, drug for combined use, and use

Purinostat mesylate (PM) for preventing and treating diffuse large B-cell lymphoma (DLBCL), an analogue thereof, a drug for combined use, and the use. PM exhibits excellent in-vivo and in-vitro anti-tumor therapeutic effects on DLBCL (DEL and DHL) subtypes with poor prognosis, DLBCL subtypes having TP53 deletion and mutation combined with a plurality of poor prognosis gene mutations, and DLBCL having TP53 mutation with double expressors, which are superior to that of most existing DLBCL clinical therapy plans. A doublet or triplet therapy of PM with rituximab, R-CHOP, venetoclax and R-CHP also exhibits excellent in-vivo therapeutic effects against DLBCL and a plurality of subtypes. Thus, PM and the drug for combined use have an important clinical significance for the DLBCL and a plurality of subtypes.
Owner:CHENGDU ZENITAR BIOMEDICAL TECH CO LTD

Application of nitroimidazole derivative and combined drug in preparation of drug for resisting drug-sensitive tuberculosis

The invention discloses application of a nitroimidazole derivative and a combined drug in preparation of a drug for resisting drug-sensitive tuberculosis, and belongs to the technical field of biological medicine. The invention provides application of a nitroimidazole derivative and a combined drug in preparation of a drug for resisting drug-sensitive tuberculosis in order to solve the clinical research blank of the nitroimidazole derivative in prevention and treatment of drug-sensitive tuberculosis. Animal experiments, I-stage clinic, II-stage clinic and medication dosage and mode optimization prove that the nitroimidazole derivative has no obvious drug accumulation, no obvious reproductive toxicity, no obvious cardiotoxicity and no QT interval extension, and compared with existing drugs such as deramanib, the nitroimidazole derivative is shorter in treatment time, more remarkable in curative effect, higher in safety and suitable for clinical application. Especially in lung iconography, voids of a patient are obviously reduced or focuses are obviously absorbed, so that the compound is expected to be used as a new medicine for preventing and treating drug-sensitive pulmonary tuberculosis.
Owner:WESTVAC BIOPHARMA TECH (BEIJING) CO LTD

Combined medication drug response prediction model based on multi-omics data and transfer learning and application

The invention discloses a drug response prediction model for drug combination based on multi-omics data and transfer learning and application, belongs to the technical field of drug response prediction, and solves the problems that a traditional method is lack of a drug response prediction system based on dosage, is mostly based on single drug response prediction, is lack of modeling ability for drug combination, and cannot predict drug response. Meanwhile, the cost is high, the period is long, and individual differences cannot be reflected. According to the prediction model, digital characteristic data, drug dosage and cell line multi-omics data of drugs are integrated, the prediction model adopts a combined transfer learning algorithm, parameters of a single drug response model are migrated into a drug combination model, a gene function module is introduced to enhance the interpretability of the model, and the prediction model can be applied to drug combination. Four cross validation strategies are adopted for evaluation of the prediction model, so that the drug response of drug combination of different candidate drugs is predicted, the method can be used for predicting the response of the drug combination, and the optimal drug combination and dosage are recommended.
Owner:PEKING UNIVERSITY SHENZHEN HOSPITAL

Application of G quadruplex ligand and entecavir combined drug in resisting HBV (Hepatitis B Virus) infection

The invention discloses an application of a G quadruplex ligand and entecavir combined drug in resisting HBV (hepatitis B virus) infection, and relates to the technical field of HBV treatment drugs. The invention determines that a G quadruplex sequence and a G quadruplex structure exist in an HBV genome, G quadruplex ligands TMPyP4 and BRACO19 can be combined with the HBV G quadruplex structure and inhibit transcription and translation of HBV, and TMPyP4 and existing clinical drug ETV combined medication have obvious synergistic effect, which indicates that the HBV G quadruplex can be used as a new drug target for resisting virus infection. The results of the invention can provide new tools and ideas for clinical prevention and treatment of hepatitis B, especially have broad prospects in the aspects of development, clinical application and the like of anti-hepatitis B drugs and vaccines, and can also be directly applied to the field of scientific research or guide the development of inhibitors for inhibiting HBV life cycle. The invention has important application value for obtaining new anti-HBV drug targets and screening new drugs.
Owner:WUHAN UNIV

Pharmaceutical composition for treating osteosarcoma and application thereof

The invention discloses a pharmaceutical composition for treating osteosarcoma and application of the pharmaceutical composition, and particularly belongs to the field of biological medicine. The pharmaceutical composition comprises cis-platinum and daidzin, the daidzin provided by the invention is combined with beta-catenin protein, so that the protein stability of the beta-catenin protein is reduced, and a Wnt signal channel is further inhibited, so that the activity of osteosarcoma cells is inhibited, cell apoptosis is induced, and pulmonary metastasis is inhibited; the pharmaceutical composition of cis-platinum and daidzin provided by the invention has a synergistic effect, the sensitivity of cells to cis-platinum is remarkably improved, and the daidzin and cis-platinum combined medication has a remarkable inhibition effect on the activity and migration invasion ability of osteosarcoma cells.
Owner:THE THIRD AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY (GUANGZHOU SEVERE MATERNAL TREATMENT CENTER GUANGZHOU ROUJI HOSPITAL)

Application of PWWP2B as target spot in preparation of leukemia treatment medicine

The invention relates to application of PWWP2B as a target spot in preparation of leukemia treatment drugs, and belongs to the technical field of biological medicines. In order to solve the problem that a traditional AML treatment target is lack of tumor specificity and is difficult to meet clinical requirements, the invention provides application of PWWP2B as a target in preparation of leukemia treatment drugs. The invention proves that PWWP2B is highly expressed in acute myelogenous leukemia cells, and the PWWP2B as a molecular marker can accurately distinguish acute myelogenous leukemia from normal healthy people or non-leukemia patients. In-vivo and in-vitro experiments prove that by knocking out PWWP2B, proliferation and clone formation of acute myelogenous leukemia cells can be remarkably inhibited, differentiation and apoptosis of the acute myelogenous leukemia cells are promoted, and activity of leukemia cells in a patient body is inhibited. The invention discloses the new application of the small molecule compound EZM0414 in treating acute myelogenous leukemia for the first time, and the synergistic interaction of the small molecule compound EZM0414 and a methylase inhibitor can be realized.
Owner:HARBIN MEDICAL UNIVERSITY

Application of combination of indobufen and butylphthalide in preparation of medicine for preventing and / or treating cerebrovascular diseases

The invention provides an application of combination of indobufen and butylphthalide in preparation of a drug for preventing and / or treating cerebrovascular diseases, indobufen and butylphthalide are combined for use, have a synergistic effect, remarkably improve the treatment effect, can be used for preparing the drug for preventing, secondarily preventing or treating the cerebrovascular diseases, and has a wide application prospect. The medicine is especially suitable for treating cerebral apoplexy and transient ischemic attack, and can be used for prophylactically improving cerebral infarction caused by cerebral arterial thrombosis.
Owner:HANGZHOU ZHONGMEI HUADONG PHARMACEUTICAL CO LTD

Method of treating SCLC and managing thrombocytopenia

ActiveUS12778951B2Anti-emeticDosing drugs
Provided are methods for the treatment of SCLC patients by administering therapeutic amounts of lurbinectedin by intravenous infusion. Also provided are methods of treating cancer by administering lurbinectedin in combination with other anticancer drugs, in particular topoisomerase inhibitors. The invention further relates to the administration of lurbinectedin in combination with anti-emetic agents for effective control of symptoms related to nausea and vomiting, reduced lurbinectedin dosages to achieve a safer administration and an increase in the number of treatment cycles. Stable lyophilized formulations of lurbinectedin are also provided.
Owner:PHARMA MAR SA

Application of an integrin αv inhibitor combined with a γ-secretase inhibitor in the preparation of drugs for treating tumors

This invention discloses the application of integrin αv inhibitors combined with γ-secretase inhibitors in the preparation of drugs for treating tumors. The study found that the combined use of integrin αv inhibitors and γ-secretase inhibitors in tumor treatment exhibits a synergistic effect, not only inhibiting in situ tumor growth but also significantly suppressing tumor invasion, distant metastasis, and other malignant progression, thus helping to slow tumor progression, improve treatment efficacy, and enhance patient prognosis. Furthermore, the study found that the combined use of integrin αv inhibitors and γ-secretase inhibitors can reduce the production of the intracellular free domain of integrin αv and inhibit the activation of the classical downstream pathway of integrin αv. The combined use of integrin αv inhibitors and γ-secretase inhibitors shows broad application prospects in tumor treatment.
Owner:SUN YAT SEN UNIV +1

Application of FN1 in treatment of mycobacterial infection

The invention belongs to the technical field of medicines, and particularly discloses application of fibronectin 1 (FN1) in treatment of mycobacterial infection. The invention finds that the FN1 has new application, and the survival of mycobacteria can be inhibited when the FN1 is independently applied; in a mycobacterium infection model, after the FN1 protein is exogenously added, the number of mycobacteria in macrophages is remarkably reduced; on the contrary, after the FN1 is knocked down, the number of mycobacteria in the macrophage is obviously increased. Further mechanism research shows that the FN1 affects release of reactive oxygen species (ROS) and cytokines by regulating a PI3K / AKT signaling pathway, and further removes mycobacteria in macrophages. From the perspective of host immunity, the invention discloses a mechanism that FN1 affects ROS (reactive oxygen species) and inflammatory response by regulating a PI3K / AKT signal channel so as to inhibit mycobacteria, and a new medicine is provided for treatment of mycobacteria infection. On the basis, FN1 can be independently used or combined with first-line antituberculosis drugs, and a new means is provided for solving the problem of drug resistance in mycobacterium infection treatment.
Owner:CHONGQING MEDICAL UNIVERSITY

Composition containing zolpidem tartrate and trazodone hydrochloride as well as preparation and application thereof

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a composition containing zolpidem tartrate and trazodone hydrochloride as well as a preparation and application of the composition, the trazodone hydrochloride can treat sleep disorders under the condition of single use and can remarkably treat the sleep disorders when being combined with zolpidem tartrate, and pharmacological experiments find that the trazodone hydrochloride can be used for treating the sleep disorders. The sleep latency can be remarkably shortened and the sleep time can be prolonged by combined medication; the content of 5HT and NE in blood is improved.
Owner:BEIJING TONGREN HOSPITAL AFFILIATED TO CAPITAL MEDICAL UNIV

A combination of r-ketorolac, bumetanide and niflumic

PCT designated stageWO2026047515A1Antineoplastic agentsOsmotic deliveryBumetanideActive agent
The present invention relates to a pharmaceutical composition for use in the treatment of both low-grade and high-grade glioblastoma in a human subject. The composition comprises a synergistic combination of the following active agents: R-Ketorolac, Bumetanide, and Niflumic acid. This specific combination is designed to exert a synergistic therapeutic effect against glioblastoma by targeting multiple molecular pathways involved in tumor progression, inflammation, and ion transport. In a further aspect of the invention, there is provided a method for selecting a subpopulation of glioblastoma subjects who are responsive to the aforementioned treatment. This method comprises identifying genetic profiles predictive of a favorable therapeutic response to the combined administration of R-Ketorolac, Bumetanide, and Niflumic acid.
Owner:GLIOGUARD SRL

Use of iPSC-induced differentiation into pancreatic progenitor cells combined with medication to treat diabetes

The present invention relates to the biological field. Further, the present invention provides the use of iPSC induced differentiation into pancreatic progenitor cells combined with medication for the treatment of diabetes. Specifically, the present invention provides a monoclonal antibody that specifically inhibits the activity of BMP4, which can inhibit the differentiation of iPSC cells into common osteoblasts and adipocytes by inhibiting the activity of BMP4 protein, thereby promoting the transformation of iPSC into pancreatic progenitor cells and differentiation into islet-like cells. After the islet-like cells and ginsenoside Rb3 are combined to prepare a drug kit, the effect of lowering blood sugar can be significantly improved, and it has a good prospect for drug application.
Owner:YU PLATINUM REFINED BIOTECHNOLOGY (CHENGDU) CO LTD

Application of benzimidazole compound drug combination in treatment and prevention of leukemia related diseases

The invention relates to a combined application of a benzimidazole compound and a BCR-ABL1TKI inhibitor in preparation of a medicine for treating leukemia related diseases, and provides a combined application of the benzimidazole compound and the BCR-ABL1TKI inhibitor in preparation of a medicine for preventing or treating leukemia related diseases.
Owner:JIANGSU HANSOH PHARMA CO LTD +1

Method for guiding accurate medication by using tumor organ-like chip and application thereof

The invention relates to the technical field of organ chip application, and relates to a method for guiding accurate medication by using a tumor organ chip, and the method comprises the following specific steps: S1, constructing a vascularized co-culture organ chip; s2, performing drug sensitivity detection aiming at an anti-tumor drug combination scheme; s3, for the screened optimal drug combination, selecting a biomarker related to the sensitivity of the drug combination; s4, constructing a drug sensitivity prediction model according to the screened gene mutation and gene abnormal expression significantly related to the drug sensitivity; and S5, performing drug sensitivity evaluation on the patient according to the drug sensitivity prediction model, and taking an evaluation result as a reference basis for individual medication guidance. The constructed method and the drug sensitivity prediction model can have the advantages of tumor microenvironment simulation and high-throughput detection at the same time; and a basis can be provided for individual medication guidance of drugs.
Owner:SOUTHEAST UNIV NANJING INST OF BIOMATERIALS & MEDICAL DEVICES

Kit for predicting treatment effect of cervical cancer drug combination composition

The invention discloses a kit for predicting the treatment effect of a combined drug composition for cervical cancer, which predicts the treatment effect of a'VEGFR inhibitor + PD-1 monoclonal antibody 'combined scheme by detecting serum arginine or SLC6A14 expression quantity in cervical cancer tissues, can help patients to select the treatment scheme in a more targeted manner, can improve the effectiveness of drug use, and has the advantages of simple operation, low cost and high efficiency. And poor prognosis or treatment opportunity delay caused by selection of treatment schemes is avoided, and the method has a good application prospect.
Owner:SUN YAT SEN UNIVERSITY CANCER CENTER (CANCER HOSPITAL AFFILIATED TO SUN YAT SEN UNIVERSITY CANCER RESEARCH INSTITUTE OF SUN YAT SEN UNIVERSITY)

Personalized prediction system for clinical curative effect of phlegm-heat clearing injection

The invention provides a personalized prediction system for the clinical curative effect of a phlegm-heat clearing injection. The personalized prediction system comprises an input module, a curative effect prediction module and an output module. The input module is used for acquiring the basic condition of a to-be-predicted patient, the combined medication information and the injection time of the phlegm-heat clearing injection; the curative effect prediction module is used for predicting the ideal probability value of the clinical curative effect of a to-be-predicted patient under different combined medication treatment schemes by using the established personalized prediction model for the clinical curative effect of the phlegm-heat clearing injection by taking the C-reactive protein as an outcome index; and the output module is used for outputting probability values of ideal clinical curative effects of the to-be-predicted patient under different combined medication treatment schemes. Based on the screened 13 indexes, the XGBoost model is adopted to construct the personalized prediction model and the prediction system for the clinical curative effect of the phlegm-heat clearing injection, and the optimal personalized treatment scheme of the phlegm-heat clearing injection and the combined drug thereof is rapidly, accurately and efficiently determined.
Owner:THE SECOND AFFILIATED HOSPITAL OF NAVAL MEDICAL UNIVERSITY PLA

Application of combination of IL-28A and Anti-PD-1 antibodies in preparation of colon cancer drugs

The invention provides an application of combination of IL-28A and Anti-PD-1 antibodies in preparation of colon cancer drugs, and belongs to the technical field of biological medicines. The invention provides an application of IL-28A in preparation of an Anti-PD-1 antibody immune checkpoint sensitizer, and provides an application of combination of the IL-28A and an Anti-PD-1 antibody in preparation of a medicine for treating colon cancer. Through an intraperitoneal injection method, the result shows that the tumor can be gradually reduced and finally disappears when the IL-28A and the Anti-PD-1 are combined for treating the subcutaneous MC38 tumor of a mouse, and a remarkable synergistic effect can be generated when the IL-28A and the Anti-PD-1 antibody are combined for medication, so that the regression of the colon cancer tumor is facilitated.
Owner:JINING MEDICAL UNIV

Application of matrine combined with medroxyprogesterone acetate in preparation of antitumor drugs

The invention belongs to the technical field of medicinal chemistry, and particularly relates to application of matrine combined with medroxyprogesterone acetate in preparation of antitumor drugs. According to the invention, matrine and medroxyprogesterone are combined for use, and the matrine and medroxyprogesterone are used for developing products such as drugs, preparations, kits and the like for treating endometrial cancer. Experimental results prove that after sophocarpidine and medroxyprogesterone acetate are combined for medication, the composition shows relatively strong activity of inhibiting endometrial cancer and relatively good synergistic inhibition effect, so that the composition has relatively good practical application value. Experimental results prove that the dosages of the two can be remarkably reduced after drug combination, and the anti-tumor effect is remarkably improved. Animal experiments show that in-vivo anti-tumor effects of sophocarpidine and medroxyprogesterone acetate can be improved by combined medication compared with that of single medication. In conclusion, the combined medication of the matrine and the medroxyprogesterone can become a new method for treating endometrial cancer patients.
Owner:HENAN UNIVERSITY

Application of TPRA1 in anti-tumor effect of oncolytic virus

The invention belongs to the field of biological medicine, and particularly relates to application of TPRA1 in the anti-tumor effect of oncolytic viruses. The invention provides the application of the oncolytic virus in preparation of the TPRA1 high-expression tumor medicine and the application of the TPRA1 accelerant in preparation of the oncolytic virus anti-tumor synergist or the drug resistance reversal agent for the first time. On the basis, the application of a substance for detecting the TPRA1 in preparation of products for oncolytic virus anti-tumor curative effect evaluation, oncolytic virus anti-tumor prognosis evaluation, tumor treatment scheme selection and / or tumor diagnosis or prognosis evaluation is provided for the first time; meanwhile, it is proved that the antitumor effect can be remarkably improved through combined medication of the oncolytic virus and the TPRA1 accelerant.
Owner:SUN YAT SEN UNIV